C Kola, MD, MBChB, FFPM

Executive Director, Medical Safety Assessment Therapeutic Area Lead , Solid Tumor Oncology
Bristol Myers Squibb

Poster(s):

• (87) Use of Immunosuppressive Drugs (ISD) and The Effectiveness of Immune Checkpoint Inhibitor (ICI) Therapy Among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) in the United States (US)
  Saturday, August 27, 2022

  8:00 AM – 6:00 PM CEST